INSIGHTS Insights for 6-27-19 By Staff Wednesday, June 26, 2019 11:55 AM "This is yet another transaction driven by diversification, scale and low borrowing costs, rather than portfolio or top line synergies."-SVB Leerink analyst Geoffrey Porges, in a note to clients following the announcement Tuesday that AbbVie will buy Allergan in a $63 billion deal, as reported by Reuters.